Investing in vaccines for developing countries: How public-private partnerships can confront neglected diseases.
This commentary discusses the barrier of vaccine price on sustainable immunization programs in developing countries and offers examples of new mechanisms driven by public-private partnerships to overcome issues of affordability. These mechanisms include Advance Market Commitments with vaccine manufacturers, which take a demand-pull approach to ensure increased production of available vaccines or development of new vaccines for neglected diseases. A second approach applies a supply-push mechanism, such as technology transfer to developing-country manufacturers. A public-private partnership that set long-term, maximum public-sector pricing to increase access of a Japanese encephalitis vaccine for the developing world is highlighted. Lessons learned from this experience can be applied to address common obstacles to new vaccine introduction in resource-limited countries, including issues of affordability, manufacturing capacity, equity in access and quality assurance.
Yaïch
Mansour
M
PATH, Seattle, WA, USA. myaich@path.org
D003140:Communicable Disease Control / Q000458:organization & administration*; D003906:Developing Countries; D004672:Encephalitis, Japanese / Q000453:epidemiology* / Q000517:prevention & control*; D006801:Humans; D022321:Japanese Encephalitis Vaccines / Q000191:economics* / Q000276:immunology*; D055818:Public-Private Sector Partnerships
D022321:Japanese Encephalitis Vaccines